Formula I Compounds for Insulin Resistance and Metabolic Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes and insulin resistance syndrome are inadequate due to side effects and lack of effective oral therapeutic agents, and there is a need for safer and more effective treatments for fatty liver disease.
Innovation Solution
A biologically active compound of Formula I is used to treat insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis, or arteriosclerosis, administered in a pharmaceutical composition with a pharmaceutically acceptable carrier, demonstrating activity in animal models of diabetes and insulin resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing diabetes treatments (insulin releasers, biguanides, insulin sensitizers) are used, then glycemic control is improved, but side effects increase (hypoglycemia, liver toxicity, weight gain)
Solution Approach 1:
The patent applies parameter changes by developing a novel chemical compound structure (Formula I) with specific molecular characteristics that differ from existing diabetes medications. The compound features a core structure with variable substituents (R1-R6, R8-R15) that can be modified to optimize therapeutic efficacy while minimizing side effects. This structural parameter change enables improved glycemic control through a different mechanism of action that avoids the harmful effects of current treatments.
2Ease of operation
If orally active therapeutic agents are developed, then treatment convenience is improved, but safety and efficacy are compromised
Solution Approach 1:
The patent employs composite material principles by creating a complex molecular structure that combines multiple functional groups and substituents in a specific arrangement. The compound of Formula I integrates various chemical moieties that work synergistically to achieve both oral bioavailability and therapeutic efficacy. This composite structural approach allows the molecule to undergo appropriate metabolic processing while maintaining effectiveness in treating insulin resistance and related conditions.
3Reliability
If insulin sensitizers (thiazolidinedione derivatives) are used, then peripheral insulin responsiveness is improved, but adverse effects increase (weight gain, edema, liver toxicity)
Solution Approach 1:
The patent applies copying principles by designing a new chemical scaffold that replicates the desired pharmacological effect of insulin sensitizers without copying their harmful side effect profile. The compound of Formula I represents a novel structural copy that achieves peripheral insulin sensitization through a different molecular architecture, thereby avoiding the weight gain, edema, and liver toxicity associated with thiazolidinedione derivatives while maintaining the beneficial effect of improved insulin responsiveness.
Data Source
AI summary
A biologically active agent, wherein the agent is a compound of the formula:Wherein A, R5, R9, X, Q and n, m, q are defined herein below.